Caxton Associates LP decreased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 53.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 55,745 shares of the biopharmaceutical company’s stock after selling 64,036 shares during the quarter. Caxton Associates LP’s holdings in Sage Therapeutics were worth $1,045,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the business. Baker BROS. Advisors LP acquired a new position in shares of Sage Therapeutics in the 1st quarter valued at $7,631,000. Bellevue Group AG increased its position in shares of Sage Therapeutics by 27.1% during the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after purchasing an additional 952,193 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Sage Therapeutics by 69.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock valued at $15,217,000 after purchasing an additional 333,805 shares during the last quarter. Lazard Asset Management LLC bought a new position in Sage Therapeutics during the 1st quarter valued at about $127,000. Finally, Seven Eight Capital LP lifted its holdings in Sage Therapeutics by 117.8% during the 1st quarter. Seven Eight Capital LP now owns 45,494 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 24,610 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.
Sage Therapeutics Trading Down 2.0 %
Shares of NASDAQ:SAGE traded down $0.22 on Tuesday, hitting $10.59. The company had a trading volume of 358,059 shares, compared to its average volume of 1,105,674. Sage Therapeutics, Inc. has a 1-year low of $9.73 and a 1-year high of $37.17. The stock has a market cap of $637.31 million, a price-to-earnings ratio of -1.28 and a beta of 0.90. The stock has a 50 day moving average price of $11.27 and a 200 day moving average price of $16.58.
Wall Street Analyst Weigh In
Check Out Our Latest Report on SAGE
Sage Therapeutics Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Featured Stories
- Five stocks we like better than Sage Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Learn Technical Analysis Skills to Master the Stock Market
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report).
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.